Vitamin C vs. Cancer: Was Linus Pauling Ahead of Medicine by 50 Years?

For nearly half a century, Vitamin C vs. Cancer has been one of medicine’s most contentious debates. Mention Linus Pauling and high-dose vitamin C to many physicians and you may still get an eye roll. Pauling’s enthusiasm for vitamin C late in his career was often portrayed as an unfortunate obsession by an otherwise brilliant scientist. But what if Linus Pauling was not a crackpot when it came to vitamin C and cancer? What if he was simply decades ahead of his time?

That question seems especially relevant now. New research published in the journal Cancer (October 1, 2026) reports a surprising survival signal in people with precancerous blood disorders and early-stage blood cancers who took an ordinary oral dose of vitamin C.

And another randomized clinical trial, this one from researchers at the University of Iowa, found that high-dose intravenous vitamin C added to standard treatment nearly doubled median survival in people with metastatic pancreatic cancer.

Those are two very different studies using two very different approaches to vitamin C.

But together they raise an uncomfortable question:

Did medicine dismiss Linus Pauling’s ideas about vitamin C and cancer before science had the tools to test them properly?

A Brand-New Vitamin C vs. Cancer Study:

The newest research comes from Denmark and the United States. The EVITA trial was a double-blind, randomized, placebo-controlled phase 2 study involving 109 people with either clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies.

CCUS is a precancerous blood disorder involving abnormal blood-forming cells. Some people with these conditions eventually develop serious diseases such as myelodysplastic syndromes or acute myeloid leukemia.

Participants were randomly assigned to receive either placebo or 1,000 mg of oral vitamin C daily for 12 months. The investigators had a very specific primary goal. They wanted to know whether vitamin C would slow the growth of abnormal blood-cell clones. It did not.

There was no statistically significant difference between the groups on that primary endpoint. That sounds disappointing.

But then something unexpected happened. During a median follow-up of nearly three years, 24 people in the placebo group died compared with 11 people assigned to vitamin C. The researchers calculated a hazard ratio for overall survival of 0.35. In other words, during the follow-up period, the vitamin C group experienced a substantially lower rate of death.

Median overall survival in the placebo group was 42.2 months. Median survival had not yet been reached in the vitamin C group when the study ended. That survival analysis was exploratory rather than the trial’s original primary endpoint, so the investigators appropriately called for a larger phase 3 study.

But that is one heck of a signal to investigate!

There Was Another Positive Vitamin C vs. Cancer Surprise:

Serious adverse events occurred in 57% of patients receiving placebo compared with 33% of those taking vitamin C. Researchers also measured inflammatory cytokines and chemokines. Several changed differently in the two groups. For example, IL-6, IL-10 and several other inflammatory signaling molecules increased more in the placebo group.

Vitamin C did not accomplish what researchers originally expected it to do. It did not significantly slow clonal growth. Nevertheless, something biologically interesting seemed to be happening.

There is another finding that caught our attention.

At the beginning of the study, 57% of participants had vitamin C blood levels classified as deficient or inadequate. These were patients receiving sophisticated hematological care in Denmark and the United States.

Perhaps nutritional status deserves a little more attention than it normally receives in oncology.

Why Might Vitamin C Matter in Blood Cancer?

The new findings did not come out of thin air. Almost a decade ago, scientists reported in Nature (Sept. 28, 2017) that blood-forming stem cells contain unusually high concentrations of vitamin C. When researchers depleted vitamin C in mice, the animals experienced changes in blood-forming stem cells that promoted leukemia development. The effect involved, at least in part, a tumor-suppressor enzyme called TET2.

TET2 matters because mutations in the gene that makes this enzyme are frequently found in myeloid blood cancers. Vitamin C acts as a cofactor for TET enzymes and influences DNA demethylation and gene regulation. In the laboratory, restoring vitamin C could reverse some of the abnormalities and suppress leukemia development in experimental animals.

That research provided a biological rationale for testing vitamin C in human beings with early-stage myeloid disorders. Now researchers have done exactly that.

Who Was Linus Pauling?

Before we return to cancer, we need to remember who Linus Pauling actually was. A lot of our younger readers have no clue who this amazing man was.

• Pauling received the 1954 Nobel Prize in Chemistry for his research on the nature of the chemical bond.
• He later received the 1962 Nobel Peace Prize for his campaign against nuclear weapons testing.
• He remains the only person ever to receive two unshared Nobel Prizes.

And yet his advocacy of vitamin C badly damaged his standing within much of the medical community.

By the 1970s, Pauling had begun collaborating with Scottish surgeon Ewan Cameron. Cameron had been giving large amounts of vitamin C to people with advanced cancer. Their treatment included intravenous vitamin C followed by oral supplementation.

Cameron and Pauling published results involving 100 terminal cancer patients in the Proceedings of the National Academy of Sciences.(Sept. 1978). They reported prolonged survival in patients receiving supplemental ascorbate compared with historical controls. The work created enormous controversy.

The Mayo Clinic Tested Vitamin C:

Researchers at the Mayo Clinic subsequently conducted randomized trials of high-dose vitamin C in patients with advanced cancer. They found no survival benefit. For many physicians, that settled the question: Cameron and Pauling were wrong!

Vitamin C did not work against cancer. End of story. Except it wasn’t.

There was a crucial difference between what Cameron and Pauling had done and what the Mayo Clinic researchers tested.

The Mayo Clinic trials used oral vitamin C.

Cameron and Pauling had used both intravenous and oral vitamin C.

At the time, researchers did not appreciate just how dramatically those two routes of administration differ. Today we know they are pharmacologically worlds apart. The National Cancer Institute now points out that oral vitamin C produces tightly controlled blood concentrations, generally below about 300 micromoles per liter.

Intravenous vitamin C bypasses intestinal absorption and kidney regulation and can produce concentrations measured in millimoles rather than micromoles. Those concentrations can be tens or even hundreds of times higher.

The National Cancer Institute itself notes that the Mayo trials used oral vitamin C whereas Cameron and Pauling had employed intravenous treatment as well. That difference turns out to be enormously important.

Oral Vitamin C Is Not IV Vitamin C:

Most people think of vitamin C as an antioxidant. At ordinary nutritional concentrations, that is largely how it behaves. But at the extraordinarily high concentrations achieved through intravenous administration, vitamin C can behave differently.

Pharmacological ascorbate can act as a pro-oxidant, producing hydrogen peroxide and other reactive oxygen species in the environment surrounding susceptible tumor cells. This is one reason modern cancer researchers became interested again in an idea that mainstream medicine had largely abandoned.

And that brings us to one of the most provocative cancer studies we have encountered.

High-Dose IV Vitamin C vs. Cancer of the Pancreas:

Pancreatic cancer is one of the most difficult malignancies to treat. Researchers at the University of Iowa conducted a randomized clinical trial in people with stage IV metastatic pancreatic cancer (Redox Biology, Nov. 2024).

Everyone received conventional treatment with gemcitabine and nab-paclitaxel. Half the patients also received 75 grams of intravenous vitamin C three times a week.

Thirty-six patients were randomized and 34 received their assigned treatment. The results were startling!

Median overall survival for people receiving standard treatment alone was:

8.3 months

For patients who also received high-dose IV vitamin C:

16 months

Median progression-free survival increased from 3.9 months to 6.2 months.

Adding IV vitamin C did not increase the frequency or severity of adverse reactions, and it did not adversely affect quality of life.

Read those numbers again.

8.3 months versus 16 months.

Here at The People’s Pharmacy we always like to go to the source. If you would like to listen to one of the researchers who helped design and run this study, why not listen to our podcast about the research. Show 1431 discussed both vitamin C against colds and vitamin C vs. cancer of the pancreas. You can listen to the streaming audio at this link.

This was admittedly a small study and desperately needs confirmation in a much larger clinical trial. But imagine for a moment that those results had been produced by a brand-new patented cancer drug.

Would anyone have noticed? We suspect so.

Now Meet Daraxonrasib:

At the 2026 annual meeting of the American Society of Clinical Oncology, investigators unveiled the results of a phase 3 trial of a new pancreatic cancer drug called daraxonrasib. This was a large and important study involving 500 people with metastatic pancreatic ductal adenocarcinoma whose cancer had already been treated.

Patients receiving daraxonrasib survived a median of:

13.2 months

Those receiving chemotherapy survived:

6.7 months

The findings were unquestionably impressive.

The results were published in the New England Journal of Medicine and presented at the ASCO meeting.

According to The BMJ (June 4, 2026) the presentation generated a standing ovation, and some members of the audience were reportedly in tears. We understand the excitement. Pancreatic cancer is devastating. Any meaningful improvement in survival deserves serious attention.

But now go back to those University of Iowa numbers.

Standard chemotherapy:

8.3 months

Chemotherapy plus IV vitamin C:

16 months

• There was no standing ovation.
• Where were the thousands of words proclaiming a potential breakthrough? We did not see them!
• There was no rush to organize a 500-patient trial to see whether the finding could be reproduced.

Mostly, we heard crickets from the oncology community.

We Are NOT Saying Vitamin C Beat Daraxonrasib:

Someone is sure to accuse us of comparing apples and oranges, so let’s deal with that issue directly. The two studies cannot be compared head-to-head. The vitamin C study involved only 36 randomized patients and tested IV vitamin C added to first-line chemotherapy.

The daraxonrasib trial involved 500 patients and studied a new treatment in people whose metastatic pancreatic cancer had already been treated. So, the researchers studied different patients in different treatment settings with different control groups. These trials were different!

We cannot conclude from these studies that vitamin C is “better” than daraxonrasib.

But we can ask why a randomized trial in which median survival increased from 8.3 to 16 months did not trigger far more enthusiasm and a major confirmatory trial. That question still deserves an answer.

The earlier People’s Pharmacy article on pancreatic cancer made exactly this point: the University of Iowa randomized trial produced a striking signal, yet the response was modest compared with the attention surrounding daraxonrasib.

By the way, in unbelievably record time the FDA approved daraxonrasib (brand name Rasonque) on August 26, 2026. And the cost of this “breakthrough” drug is somewhere between about $40,000 and $48,000 a month. If a person lives an extra year thanks to Rasonque, the total cost could approach $500,000.

Was Linus Pauling Ahead of Medicine?

This brings us back to Linus Pauling. More than 50 years ago, Pauling and Cameron believed that vitamin C could have a role in cancer treatment. Their early research was far from definitive. It lacked the rigorous randomized design that modern medicine expects.

Later oral-vitamin-C trials failed. For years, that failure became shorthand for:

Vitamin C doesn’t work against cancer.

But science moved on. Researchers discovered that oral and intravenous vitamin C produce radically different blood concentrations. Scientists uncovered new biochemical mechanisms through which pharmacological ascorbate might damage cancer cells. Researchers discovered connections among vitamin C, TET enzymes, DNA regulation and leukemia. And now randomized trials have produced provocative findings in both metastatic pancreatic cancer and early myeloid blood disorders.

That does not mean Linus Pauling got everything right. Science rarely works that way. But his basic proposition — that vitamin C deserved serious investigation as part of cancer treatment — no longer looks nearly as outlandish as it once did.

Perhaps Pauling’s greatest mistake was not the idea itself. Perhaps it was having the idea before medicine understood enough biochemistry to test it properly.

Why Hasn’t IV Vitamin C Become a Cancer Treatment?

There are legitimate reasons for caution. The pancreatic cancer trial was small. Small studies sometimes produce spectacular results that disappear when hundreds of patients are studied. The new EVITA blood-cancer trial also has limitations. Its primary endpoint was negative, and the survival analysis was exploratory. Neither study establishes vitamin C as a cancer cure.

Neither study means people should substitute vitamin C for proven cancer treatments. The FDA has not approved high-dose IV vitamin C as a cancer treatment. But none of those facts explains why larger definitive trials should not be conducted.

In our opinion, the University of Iowa pancreatic cancer results cry out for replication. If a safe, inexpensive, nonproprietary substance can meaningfully improve survival when added to conventional treatment, patients deserve to know.

One other point: Rasonque is not a cancer cure either and yet it has had members of the oncology community standing and in tears.

Should Cancer Patients Take Vitamin C?

Please do not interpret this article as advice to treat cancer yourself with vitamin C. Taking 1,000 mg of vitamin C by mouth is nothing like receiving 75 grams intravenously under medical supervision.

High-dose IV vitamin C can also create serious problems for some people, particularly those with kidney disease or G6PD deficiency. People undergoing cancer treatment should discuss vitamin C or any other supplement with their oncology team.

But patients should also feel entitled to ask their doctors about the research. A fair question might be:

“Have you seen the randomized trial of high-dose IV vitamin C in metastatic pancreatic cancer, and what do you think of the results?”

That is not rejecting modern medicine. That is asking modern medicine to live up to its own commitment to evidence.

Vitamin C vs. Cancer: Perhaps Linus Pauling Deserves Another Look

Linus Pauling spent part of his extraordinary career promoting an idea that many physicians came to regard as scientific heresy. Half a century later, researchers are still investigating it. They have discovered mechanisms Pauling could not have known about.

They can achieve blood concentrations he could not precisely measure. And randomized clinical trials are producing results that deserve much more attention.

Was Linus Pauling ahead of medicine by 50 years? We don’t yet have a final answer. But after the pancreatic cancer trial and the new EVITA blood-cancer study, it would be hard to argue that the question is foolish.

Perhaps the most scientific response is also the simplest:

Do the larger trials.

Then follow the evidence wherever it leads.

Where Will You Find Vitamin C in Nature?

Many fruits and vegetables are rich in ascorbate, which might help explain why a diet rich in fresh produce has been linked to a lower risk of cancer. The best sources include blueberries; broccoli and cauliflower; cantaloupe and other melons; citrus fruits such as grapefruit, oranges and tangerines; cranberries; green and red peppers; mango; papaya; pineapple; raspberries; spinach and other dark green leafy vegetables; strawberries; sweet potatoes; tomatoes; and watermelon.

What Do You Think?

Are you old enough to remember the controversy over Linus Pauling and vitamin C? Have you or someone you know received intravenous vitamin C during cancer treatment? Were you able to discuss it openly with an oncologist?

We would especially like to hear from cancer specialists and researchers. Please share your thoughts and experiences in the comment section below. If you think this article has merit, please share it with friends and family members.